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INTRODUCTION
HIV is a global public health problem. In 2016, more than a
million people died from HIV-associated causes around the
world. The aim of antiretroviral therapy is to suppress viral
replication, strengthen the individual’s immune system, and
regain the capacity to resist infections. In accordance to
World Health Organization (WHO) recommendations, an-
tiretroviral therapy (ART) should be initiated in all people
living with HIV, regardless of WHO clinical stage and
CD4+ T-cell count (Anonymous, 2016a). Unfortunately,
failure is not a rare outcome of ART, which remains the
subject of empirical studies (Boettiger et al., 2014; Patrikar
et al., 2017).
ART failure is associated with a variety of factors: poor ad-
herence to medication, missed visits, a higher baseline viral
load, a lower baseline CD4+ T-cell count, a low absolute
neutrophil count, low BMI, and opportunistic infections
(Lucas et al., 1999; Lundgren et al., 2002; Robbins et al.,
2007; Patrikar et al., 2017). Treatment failure can be as-
sessed through monitoring of viral load, CD4+ T-cell count,
and a new or recurrent clinical event. In accordance with
WHO recommendations (Anonymous, 2016a), viral load
monitoring is preferred for confirming treatment failure.
However, based on a negative relationship between viral
load and CD4+ T-cell count (Pantaleo and Fauci, 1996),
CD4+ T-cell response has been preferred in monitoring the
success of ART in resource-limited settings (e.g., Keiser et
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Antiretroviral therapy (ART) aims at suppressing viral replication and strengthening immune sys-
tem in patients with HIV-1. Human Leukocyte Antigens (HLA) are among factors responsible for
effectiveness of ART. The aim of this study was to determine the effect of HLA Class II alleles on
the response to long-time ART, assessed by a change in CD4+ T-cell count in relation to viral
load. The sample included 69 patients (17 females and 52 males) aged 20 to 50 with HIV-1 infec-
tion, who were undergoing ART in the Latvian Centre of Infectious Diseases. The median period
of observation was 5.7 years. CD4+ T-cell count and viral load were analysed at the baseline and
end of the period of observation. HLA typing was performed by polymerase chain reaction with
low resolution sequence specific primers. Multiple hierarchical linear regression analysis con-
firmed that an increase in HIV-1 viral load was associated with a decrease in the level of CD4+ T-
cell count. In addition, HLA-DRB1*04 and HLA-DQB1*06:01 alleles contributed negatively to the
level of CD4+ T-cell count.
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al., 2009; Odafe et al., 2012; Montarroyos et al., 2014;
Gezie et al., 2017).
Studies have also shown that a response to ART is related
to allelic variants of different genes (Haas et al., 2005; Zhu
et al., 2005). One of the groups of these genes is the Human
Leukocyte Antigens (HLA), which are essential in the regu-
lation of immune response. Previous studies demonstrated
that HLA Class I and Class II alleles affect susceptibility to
HIV infection and development time of AIDS (Saah et al.,
1998; Keet et al., 1999), viral control in ART-naive patients
(Jugl et al., 2011; Ranasinghe et al., 2013), and adverse re-
actions during ART (Mallal et al., 2002; Pavlos et al.,
2012). In ART-naive patients, The HLA-DRB1*03:01 al-
lele (significantly) and HLA-DRB1*04:04, 01:01, 15:01,
and 08:01 alleles (with marginal significance) were shown
to be associated with high viremia (Ranasinghe et al.,
2013). At the same time, information about effect of HLA
genes on ART effectiveness is limited. In early-treated pa-
tients, the HLA-DRB1*13/HLA-DQB1*06 haplotype had a
protective effect on virological and immunological re-
sponses (Malhotra et al., 2001).
The goal of the present study was to determine the effect of
HLA Class II alleles on response to long-term ART by esti-
mating change in CD4+ T cells in relation to viral load. We
expected that alleles associated with high viremia in ART-
naive patients can negatively affect the progress in ART
(Ranasinghe et al., 2013), while protective alleles can posi-
tively affect ART (Malhotra et al., 2001).
MATERIALS AND METHODS
The study was retrospective, approved by the Central
Medical Ethics Committee, Rîga, Latvia. The sample in-
cluded 69 patients (17 females and 52 males) aged 20 to 50
(mean age was 32.68, SD = 8.38) with HIV-1 infection,
who were undergoing ART in the Latvian Centre of Infec-
tious Diseases (currently Latvian Centre of Infectious Dis-
eases of Rîga Eastern Clinical University Hospital) in the
period from 1998 till 2012. Inclusion criteria were: con-
firmed HIV-1 infection, received ART in accordance with
recommendations, and monitoring of CD4+ T-cell count
and viral load. The diagnosis of HIV-1 infection was con-
firmed by detection of specific antibodies and HIV-1 anti-
gen (ELISA) and specific antibodies to HIV-1, using the
Immunoblot and Western blot methods.
The median period of observations in the study was 5.7
years (from 4 to 7 years). All patients received ART in ac-
cordance to national recommendations: two nucleoside re-
verse transcriptase inhibitors (NRTI) combined with one
protease inhibitor (PI) or one non-nucleoside reverse tran-
scriptase inhibitor (NNRTI).
Information about patient age, sex, treatment regiment, and
compliance was collected from medical documentation. In
addition, the documentation included data on viral load and
CD4+ T-cell count at the beginning and end of the observa-
tion period. Both investigations were performed at the Lat-
vian Centre of Infectious Diseases. Viral load testing was
performed by the polymerase chain reaction. CD4+ T-cell
count was determined by flow cytometry.
The investigation of HLA class II genotype of each patient
was performed in the Joint Laboratory of Clinical Immunol-
ogy and Immunogenetics of Rîga Stradiòð University. Pe-
ripheral blood samples (5 ml) were collected in EDTA con-
taining tubes and stored at –20 °C. The QIAamp® DNA
Blood Kit (QIAGEN, Germany) was used for human DNA
extraction according to manufacturer’s instruction (Anony-
mous, 2016b). DNA amplification was performed by po-
lymerase chain reaction (PCR) with low resolution se-
quence specific primers (DNA-Technology, Russia)
according to manufacturer’s instructions (Anonymous,
2018). Each kit contained an internal control for evaluation
of PCR quality and positive control. HLA typing included
identification of HLA-DRB1* alleles (01 to 18), HLA-
DQA1* alleles (01:01, 01:02; 01:03; 01:04, 02:01; 03:01;
04:01, 05:01, 06:01), and HLA-DQB1* alleles (02:01-
02:02; 03:01-04; 04:01-04:02; 05:01-04; 05:02-03; 06:01;
06:02-08). Amplification was performed using a Real-Time
PCR Thermal Cycler “DT-Lite” with four channels and 48
wells (DNA-Technology, Russia). The reaction mixture was
subjected to 35 amplification cycles, each consisting of de-
naturation at 94 °C (60 s), followed by one cycle, annealing
at 94 °C (20 s), 67 °C (2 s) followed by seven cycles and
extension at 93 °C (5 s), 65 °C (4 s), with a final extension
instep with 35 cycles.
The statistical analysis was performed using IBM SPSS Sta-
tistics for Windows, Version 22.0. Normality of distribution
was assessed using the Shapiro–Wilk and Kolmogorov–
Smirnov tests with Lilliefors significance correction. Sig-
nificance of differences in values at two difference times
was determined using the Wilcoxon test. The relationship
between parameters was estimated using Pearson product-
moment correlation coefficient. A multiple hierarchical lin-
ear regression analysis combined a standard regression for a
change in CD4+ T-cell count predicted by a change in the
viral load and a statistical regression for the assessment of
alleles as additional predictors.
RESULTS
A quantitative analysis of the alleles was performed. Table
1 summarises the observed allele frequencies.
Table 2 presents descriptive statistics for CD4+ T-cell
count, HIV-1 viral load, and viral load (log) at the start and
end point of the observation. The Wilcoxon test revealed no
significant difference between the two times in CD4+
T-cell count and viral load.
A significant negative relationship was found between
CD4+ T-cell count and viral load viral load ( (r = –0.41, p <
0.01, n = 67).
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A multiple hierarchical linear regression was applied to de-
termine predictors of a change in the CD4+ T-cell count.
The regression model combined a standard regression for
log viral load at the first step and a statistical regression for
HLA Class II alleles at the next steps. In addition, age, sex,
and time length between first and second time points were
controlled during the analysis. Table 3 shows the results at
each step. The variance inflation factor (VIF) varied from
1.00 to 1.17 and indicated acceptable level of covariance
among the predictors. The results confirmed increase of
HIV-1 viral load as a significant predictor for an increase in
for a decrease in CD4+ T-cell count. In addition, HLA-
DRB1*04 and DQB1*06:01 alleles demonstrated a negative
contribution to the change of CD4+ T-cell count. No allele
contributed positively to CD4+ T-cell count. It should be
also noted that age, sex, and observed length of the interval
between two measures (5 to 7 years) were not significant
predictors.
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T a b l e 1
DISTRIBUTION OF HLA CLASS II ALLELES IN PATIENTS WITH











*01 26 (37.7) *01:01 17 (24.6) *02:01-02 20 (29.0)
*04 7 (10.1) *01:02 22 (31.9) *03:01 30 (43.5)
*07 12 (17.4) *01:03 11 (15.9) *03:02 10 (14.5)
*08 5 (7.2) *01:04 1 (1.4) *03:03 13 (18.8)
*09 3 (4.3) *02:01 17 (24.6) *03:04 1 (1.4)
*10 2 (2.9) *03:01 22 (31.9) *04:01-02 3 (4.3)
*11/12 28 (40.6) *04:01 3 (4.3) *05:01 18 (26.1)
*13/14 16 (23.2) *05:01 39 (56.5) *05:02 7 (10.1)
*15/16 23 (33.3) - - *05:03 1 (1.4)
*17/18 12 (17.4) - - *06:01 2 (2.9)
- - - - *06:02-08 20 (29.0)
T a b l e 2
CD4+ T CELL COUNT AND HIV-1 VIRAL LOAD AT THE BEGINNING (T0) AND THE END (T1) OF THE STUDY (n = 69)
Parameter T0 T1 Difference Wilcoxon test
M ± SD M ± SD M ± SD z p
CD4+, cells/l 468.90 ± 268.27 420.28 ± 290.03 –48.62 ± 335.20 –1.47 0.141
VL, copies/ml 1.13105 ± 2.89105 0.91105 ± 1.96105 –0.22105 ± 3.51105 –0.18 0.861
lg(VL) 3.80 ± 1.19 3.67 ± 1.28 –0.13 ± 1.65 –0.48 0.635
M, mean; SD, standard deviation; VL, HIV-1 viral load; lg, decimal logarithm.
T a b l e 3
A MULTIPLE HIERARCHICAL LINEAR REGRESSION ON A CHANGE IN THE LEVEL OF CD4+ T CELL COUNT
Predictors B SE B Â
Step 1: F (4, 64) = 3.68, p < 0.01; R2 = 0.19; adjusted R2 = 0.14.
Constant –256.28 347.29
Age 5.13 4.79 0.13
Sex 47.85 91.22 0.06
Interval between measures 0.00 0.15 0.00
Change in lg(VL) –72.54 24.25 –0.36**
Step 2: F (5, 63) = 5.33, p < 0.001; R2 = 0.30; adjusted R2 = 0.24; R2 = 0.11.
Constant –190.16 326.08
Age 3.51 4.52 0.09
Sex 47.86 85.48 0.06
Interval between measures 0.01 0.14 0.01
Change in lg(VL) –72.53 22.72 –0.36***
HLA-DRB1*04 –369.01 117.29 –0.34**
Step 3: F (6, 62) = 5.69, p < 0.001; R2 = 0.36; adjusted R2 = 0.29; R2 = 0.06.
Constant –7.52 281.44
Age 1.91 4.42 0.05
Sex 64.96 82.86 0.08
Interval between measures –0.01 0.14 –0.01
Change in lg(VL) –82.62 22.35 –0.41***
HLA-DRB1*04 –387.32 113.53 –0.35**
HLA-DQB1*06:01 –492.57 208.94 –0.25*
***
p < 0.001. ** p < 0.01. * p < 0.05. lg(VL), decimal logarithm of the viral load.
The following analysis demonstrated that haplotypes associ-
ated with revealed alleles are rarely presented. HLA-
DRB1*04/HLA-DQA1*01:04 and HLA-DRB1*06/HLA-
DQB1*06:01 were presented once. The haplotype HLA-
DQA1*01:02/HLA-DQB106:01 was observed two times,
and HLA-DRB1*04/HLA-DQB1*03:02 was identified
three times. Adding them to the analysis demonstrated no
significant change in the predicted model.
DISCUSSION
In addition to the well-known association between CD4+
T-cell count and HIV-1 viral load (Pantaleo and Fauci,
1996), the present study demonstrated effect of HLA Class
II alleles on the observed change in CD4+ T-cell count.
Among the alleles under investigation, HLA-DRB1*04 and
HLA-DQB1*06:01 demonstrated statistically significant as-
sociation with decreasing CD4+ T-cell count over the ART
period of 5 to 7 years. Taking into account that CD4+ T-cell
count is one of the key indicators of the HIV disease pro-
gression (Mellors et al., 1997; Langford et al., 2007), we
conclude that these alleles had a negative impact on ART in
the present cohort.
The observed negative impact of the HLA-DRB1*04 geno-
type on the course of HIV-1 infection during ART is in ac-
cordance with previous studies (Saah et al., 1998; Rana-
singhe et al., 2013), which showed that the HLA-DRB1*04
genotype was a HLA marker with adverse effect in HIV-1
patients.
The present study showed also negative effect of the HLA-
DQB1*06:01 allele on the HIV-1 course during long-term
ART. This is in contrast with a study (Malhotra et al., 2001)
that demonstrated a protective effect of HLA-DQB1*06:01
allele within the HLA-DRB1*13/HLA-DQB1*06 haplo-
type. Patients who inherited this haplotype had a greater
likelihood of effectively controlling HIV-1 replication dur-
ing 18 month-long ART (Malhotra et al., 2001). A possible
explanation of this effect can be associated with the time in-
terval of therapy and the cohort involved in our study.
It should be noted that the role of HLA Class II alleles in
therapy was investigated for different pathologies. In pa-
tients with multiple sclerosis receiving long-term interferon
beta therapy, 04:01 and 04:08 alleles of HLA-DRB1*04 al-
lelic group were associated with the production of antibod-
ies against interferon beta therapy leading to a less effective
interferon beta treatment (Buck et al., 2011). In addition,
the HLA-DRB1*04 allelic group had a role in predisposi-
tion to the most severe form of rheumatoid arthritis (Zanelli
et al., 2002; Balandraud et al., 2013) and more rapid disease
progression (Kapitány et al., 2008). HLA-DRB1*04 alleles,
particularly homozygosity for HLA-DRB1*04, were uni-
variate predictors of radiographic progression (Goronzy et
al., 2004). Therefore, the HLA-DRB1*04 allelic group is a
risk marker for a variety of pathologies. This conclusion in-
dicates the direction for the further study on multiple immu-
nological effects of this allelic group in therapy, including
the level of CD4+ T-cell change.
It should be noted that the present study had some limita-
tions. The number of patients under observation was rela-
tively low, which was due to socioeconomic difficulties
limiting inclusion and following patients during the study.
However, it allowed and provide an initial statistical assess-
ment. Taking into account the broad temporal interval of
observations in this study, a more coherent sample should
be preferred for the further investigation of long-time ART.
A stronger control of virological, immunological, and clini-
cal markers of treatment failure is needed for a more de-
tailed description of change dynamics.
It can be concluded that, as host genetic factors, HLA Class
II alleles can affect long-time ART and disease progression.
Our study demonstrated that HLA-DRB1*04 and HLA-
DQB1*06:01 alleles are risk markers in the Latvian cohort
of HIV-1 patients undergoing long-time ART. Information
regarding patient’s HLA Class II genotype might be helpful
to guide ART in patients with HIV-1 infection.
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CILVÇKA LEIKOCÎTU ANTIGÇNU II KLASES ALÇLES IETEKMÇ ATBILDI UZ 5–7 GADUS ILGU ANTIRETROVIRÂLO
TERAPIJU LATVIJAS PACIENTU GRUPÂ
Pacientiem ar HIV-1 infekciju antiretrovirâlâs terapijas (ART) mçríis ir nomâkt vîrusu replikâciju un nostiprinât indivîda imûno sistçmu.
Viens no faktoriem, kas ir atbildîgs par ART efektivitâti, ir gçnu grupa, kuru sauc par cilvçka leikocîtu antigçniem (HLA). Ðî pçtîjuma
mçríis bija atklât HLA II klases alçïu ietekmi uz reakciju ilgstoðas ART laikâ, novçrtçjot tâs ietekmi uz CD4+ T ðûnu skaita izmaiòâm, kad
tiek kontrolçtas vîrusu slodzes izmaiòas. Pçtîjumâ tika iekïauti 69 pacienti (17 sievietes un 52 vîrieði) vecumâ no 20 lîdz 50 gadiem ar
HIV-1 infekciju, kuriem ART tika veikta Latvijas Infektoloìijas centrâ. Vidçjais novçrojumu periods bija 5,7 gadi. CD4+ T ðûnu skaits un
vîrusu slodze tika analizçti novçroðanas perioda sâkumâ un beigâs. HLA tipizçðana tika veikta ar zemas izðíirtspçjas polimerâzes íçdes
reakciju ar sekvences specifiskiem praimeriem. Multiplâs hierarhiskâs lineârâs regresijas analîze apstiprinâja, ka HIV-1 vîrusu slodzes
palielinâðanâs paredz CD4+ T ðûnu skaita samazinâðanos. Turklât, HLA-DRB1*04 un HLA-DQB1*06:01 alçles papildus negatîvi
ietekmçja CD4+ T ðûnu skaita lîmeni.
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